Agenus appoints VP and global head of clinical development
Dr. Cuillerot has played a key role in the successful clinical development of antibodies targeting CTLA-4 and PD-L1 at global pharmaceutical companies.
Dr. Cuillerot joins the company with 16 years of experience in oncology clinical research and drug development.
Most recently, he served as the Global Head of Clinical Development, Immuno-Oncology, and Vice President of Clinical Immunotherapy/Immuno-Oncology at EMD Serono Research and Development Institute, an affiliate of Merck Serono.
At Merck Serono he oversaw the development of the company’s immuno-oncology portfolio, which included two checkpoint inhibitors and two immuno-cytokines. He also advanced the PD-L1 antibody avelumab from pre-IND to filing and was responsible for delivering the dataset leading to the deal with Pfizer.
Dr. Cuillerot led the Global Clinical Research team in all interactions with health authorities, including the FDA and EMA.
At Bristol-Myers Squibb, Dr. Cuillerot was the Medical Lead for Ipilimumab Life Cycle Management, developing strategies for the anti-CTLA-4 antibody as a treatment for lung cancer, castrate resistant prostate cancer, ovarian cancer, gastric cancer and glioblastoma.
In addition to leading the execution of clinical studies, he supported the filing activities of ipilimumab for first-line treatment of melanoma.
Dr. Cuillerot received his B.S. in biochemistry, M.D., and M.Sc. in cellular and molecular biology at the University Louis Pasteur. He is board certified in hematology and immunology. ■
What to read next
LATEST MOVES FROM Massachusetts
- PTC appoints Corinna Lathan to board
- J.Jill appoints James S. Scully to board
- Raytheon elects Robert O. Work as director
- Xenetic Biosciences appoints three directors
- Insulet appoints two to board
More inside POST